The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2022-08-19), Amgen's share price is $249.70. Amgen's Book Value per Share for the quarter that ended in Jun. 2022 was $4.52. Hence, Amgen's PB Ratio of today is 55.22.
The historical rank and industry rank for Amgen's PB Ratio or its related term are showing as below:
AMGN'
s PB Ratio Range Over the Past 10 Years
Min: 2.02 Med: 4.38 Max: 148.84
Current: 55.21
During the past 13 years, Amgen's highest PB Ratio was 148.84. The lowest was 2.02. And the median was 4.38.
AMGN's PB Ratio is ranked worse than 99.21% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 1.86
vs AMGN: 55.21
During the past 12 months, Amgen's average Book Value Per Share Growth Rate was -68.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -15.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -21.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -7.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Amgen was 69.30% per year. The lowest was -27.30% per year. And the median was 16.00% per year.
Back to Basics: PB Ratio
Amgen PB Ratio Historical Data
The historical data trend for Amgen's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Amgen Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
PB Ratio
4.98
9.81
14.74
14.13
18.75
Amgen Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
PB Ratio
16.83
14.62
18.75
141.00
53.80
Competitive Comparison
For the Drug Manufacturers - General subindustry, Amgen's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen PB Ratio Distribution
For the Drug Manufacturers industry and Healthcare sector, Amgen's PB Ratio distribution charts can be found below:
* The bar in red indicates where Amgen's PB Ratio falls into.
Amgen PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Amgen's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Amgen PB Ratio Related Terms
Thank you for viewing the detailed overview of Amgen's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.88(0.35%) Volume: 1,886,175 10:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:AMGN has been successfully added to your 
